Theradiag, a company specializing in in vitrodiagnostics and theranostics, on Thursday announced the launch of its Stelara ustekinumab monitoring test in the US market, as part of its partnership with Miraca Life Sciences.
Theradiag’s Stelara monitoring kit expands Miraca Life Sciences’ InformTxTM service in the US market, allowing monitoring of biotherapies for the treatment of inflammatory bowel disease (IBD).
InformTxTM is the only service of its kind in the USA, and now features five Theradiag monitoring tests, that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS.
“Increasing the number of drugs which we can test with our InformTx therapeutic drug monitoring allows us to provide critical information to help guide therapy for even more gastroenterologists and their patients,” said Richard Lash, MD, Chief Medical Officer and Executive Vice President of Operations for Miraca Life Sciences. “We plan to add more biologics to our InformTx testing service over time.”
Michel Finance, CEO of Theradiag, said: “Miraca Life Sciences’ US launch of our fifth monitoring test will broaden our offering in the US market, where twice as many patients are treated with biotherapies as in Europe, giving us us major sales potential in the next few years. Our Lisa Tracker biotherapy monitoring range is the most comprehensive one currently available in the global market. Our ambition is to develop monitoring kits for all biotherapies on the market, both current and future, in our key therapeutic areas of expertise, i.e. autoimmune and inflammatory diseases, and also to offer them in the US market.”